Remarks

The Office Action mailed 1/8/03 rejected claims 42-44 and 46-53 under 35 U.S.C. 102(e) over Coury et al.

Independent claim 42 has been amended to specify that the formulation is contained in a metered dose inhaler for oral and/or nasal inhalation. Support for the amendment can be found at page 8, lines 25-27, of the specification.

Coury et al. is limited to formulations suitable for cosmetic or dermatologic skin conditions, which would not include a metered dose inhaler for oral and/or nasal inhalation. It is therefore submitted that claim 42 and the dependent claims are clearly distinguished over Coury et al. Reconsideration and favorable action are therefore requested.

Registration Number 35,658 Telephone Number (651) 736-5839

Respectfully submitted,

Ted K. Ringsred

Office of Intellectual Property Counsel 3M Innovative Properties Company P.O. Box 33427

St. Paul, Minnesota 55133-3427 Facsimile: (651) 736-3833

Docket No.: 51737US019

정 Version With Markings to Show Changes Made

A sustained release medicinal aerosol formulation comprising:

- (a) a propellant;
- (b) A therapeutically effective amount of a drug; and
- No.: 517_
 RECEIVED TOO SOO a sufficient amount of a biocompatible polymer substantially completely (c) dissolved in the formulation so as to provide for sustained release of the drug; wherein the sustained release formulation results in discrete, nonfilm forming particles upon delivery, and

wherein the formulation is contained in a metered dose inhaler for oral and/or nasal inhalation.